Your browser doesn't support javascript.
loading
A trypanosome-derived immunotherapeutics platform elicits potent high-affinity antibodies, negating the effects of the synthetic opioid fentanyl.
Triller, Gianna; Vlachou, Evi P; Hashemi, Hamidreza; van Straaten, Monique; Zeelen, Johan P; Kelemen, Yosip; Baehr, Carly; Marker, Cheryl L; Ruf, Sandra; Svirina, Anna; Chandra, Monica; Urban, Katharina; Gkeka, Anastasia; Kruse, Sebastian; Baumann, Andreas; Miller, Aubry K; Bartel, Marc; Pravetoni, Marco; Stebbins, C Erec; Papavasiliou, F Nina; Verdi, Joseph P.
Afiliação
  • Triller G; Division of Immune Diversity, German Cancer Research Center, 69120 Heidelberg, Germany.
  • Vlachou EP; Division of Immune Diversity, German Cancer Research Center, 69120 Heidelberg, Germany; Panosome GmbH, 69123 Heidelberg, Germany.
  • Hashemi H; Division of Immune Diversity, German Cancer Research Center, 69120 Heidelberg, Germany.
  • van Straaten M; Division of Structural Biology of Infection and Immunity, German Cancer Research Center, 69120 Heidelberg, Germany.
  • Zeelen JP; Division of Structural Biology of Infection and Immunity, German Cancer Research Center, 69120 Heidelberg, Germany.
  • Kelemen Y; Hepione Therapeutics, Inc., New York, NY 10014, USA.
  • Baehr C; Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
  • Marker CL; Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA; Iuvo Bioscience, Rush, NY 14543, USA.
  • Ruf S; Division of Immune Diversity, German Cancer Research Center, 69120 Heidelberg, Germany.
  • Svirina A; Division of Immune Diversity, German Cancer Research Center, 69120 Heidelberg, Germany.
  • Chandra M; Panosome GmbH, 69123 Heidelberg, Germany; Division of Structural Biology of Infection and Immunity, German Cancer Research Center, 69120 Heidelberg, Germany.
  • Urban K; Division of Immune Diversity, German Cancer Research Center, 69120 Heidelberg, Germany.
  • Gkeka A; Division of Immune Diversity, German Cancer Research Center, 69120 Heidelberg, Germany; Panosome GmbH, 69123 Heidelberg, Germany.
  • Kruse S; Panosome GmbH, 69123 Heidelberg, Germany.
  • Baumann A; Cancer Drug Development Group, German Cancer Research Center, 69120 Heidelberg, Germany.
  • Miller AK; Cancer Drug Development Group, German Cancer Research Center, 69120 Heidelberg, Germany.
  • Bartel M; Forensic Toxicology, Institute of Forensic and Traffic Medicine, Heidelberg University Hospital, 69115 Heidelberg, Germany.
  • Pravetoni M; Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA; Department of Psychiatry and Behavioral Sciences, Department of Pharmacology, University of Washington School of Medicine, Center for Medication Development for Substance Use Disorders, Seattle, WA 98195,
  • Stebbins CE; Division of Structural Biology of Infection and Immunity, German Cancer Research Center, 69120 Heidelberg, Germany.
  • Papavasiliou FN; Division of Immune Diversity, German Cancer Research Center, 69120 Heidelberg, Germany.
  • Verdi JP; Division of Immune Diversity, German Cancer Research Center, 69120 Heidelberg, Germany; Hepione Therapeutics, Inc., New York, NY 10014, USA. Electronic address: j.verdi@dkfz-heidelberg.de.
Cell Rep ; 42(2): 112049, 2023 02 28.
Article em En | MEDLINE | ID: mdl-36719797
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Trypanosoma / Trypanosoma brucei brucei / Tripanossomíase Africana Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Trypanosoma / Trypanosoma brucei brucei / Tripanossomíase Africana Idioma: En Ano de publicação: 2023 Tipo de documento: Article